Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Neuroblastoma
Results 1-25 of 87 for your search:
Start Over
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 365 days to 30 years
Trial IDs: ANBL1531, NCI-2016-01734, NCT03126916
OPT-821 with Vaccine Therapy and Beta-Glucan in Treating Younger Patients with High-Risk Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: 05-075, NCI-2009-01362, NCT00911560
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Relapsed or Refractory High-Risk Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 1
Trial IDs: 12-230, NCI-2013-00007, NCT01757626
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: NMTRC010, NCI-2015-01871, NCT02139397
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Gallium Ga 68-DOTA-TOC PET/CT or PET/MRI in Imaging Patients with Somatostatin Receptor Positive Tumors
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic
Age: Over 18
Trial IDs: 14453, NCI-2017-00451, NCT02177773
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
Trial of Afatinib in Pediatric Tumours
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 17
Trial IDs: 1200.120, NCI-2016-00936, 2014-002123-10, NCT02372006
Baricitinib in Treating Chronic Graft Versus Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Supportive care
Age: 18 to 99
Trial IDs: 16-C-0094, NCI-2016-00773, NCT02759731
Pacritinib, Sirolimus, and Tacrolimus in Preventing Graft Versus Host Disease in Patients with Blood Cancer Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: MCC-18783, NCI-2017-00594, NCT02891603
A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 6 months to 18 years
Trial IDs: ONC-403-001, NCI-2017-01329, NCT02748135
Iobenguane I-131 in Treating Patients with Recurrent Neuroblastoma, Malignant Pheochromocytoma, or Malignant Paraganglioma
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 1
Trial IDs: 04-148, NCI-2016-00955, MSKCC-04148, NCT00107289
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: V0706, NCI-2014-00478, NCT00601003
Irinotecan Hydrochloride and Temozolomide with Temsirolimus or Dinutuximab in Treating Younger Patients with Refractory or Relapsed Neuroblastoma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Children
Trial IDs: ANBL1221, NCI-2012-03125, CDR0000745188, COG-ANBL1221, PANBL1221_A08PAMDREVW01, NCT01767194
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NCT01804634
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 24 months to less than 30 years
Trial IDs: N2011-01, NCI-2015-00640, NCT02035137
Proton Beam Radiation Therapy in Treating Patients with Neuroblastoma or Ganglioneuroblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 25
Trial IDs: 13-443, NCI-2014-01557, NCT02112617
Start Over